Patients' experience of screening CT colonography with reduced and full bowel preparation in a randomised trial.


Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
May 2019
Historique:
received: 18 07 2018
accepted: 27 09 2018
revised: 10 09 2018
pubmed: 8 11 2018
medline: 6 6 2019
entrez: 8 11 2018
Statut: ppublish

Résumé

To assess patients' experience of bowel preparation and procedure for screening CT colonography with reduced (r-CTC) and full cathartic preparation (f-CTC) that showed similar detection rate for advanced neoplasia in a randomised trial. Six hundred seventy-four subjects undergoing r-CTC and 612 undergoing f-CTC in the SAVE trial were asked to complete two pre-examination questionnaires-(1) Life Orientation Test - Revised (LOT-R) assessing optimism and (2) bowel preparation questionnaire-and a post-examination questionnaire evaluating overall experience of CTC screening test. Items were analysed with chi-square and t test separately and pooled. LOT-R was completed by 529 (78%) of r-CTC and by 462 (75%) of f-CTC participants and bowel preparation questionnaire by 531 (79%) subjects in the r-CTC group and by 465 (76%) in the f-CTC group. Post-examination questionnaire was completed by 525 (78%) subjects in the r-CTC group and by 453 (74%) in the f-CTC group. LOT-R average score was not different between r-CTC (14.27 ± 3.66) and f-CTC (14.54 ± 3.35) (p = 0.22). In bowel preparation questionnaire, 88% of r-CTC subjects reported no preparation-related symptoms as compared to 70% of f-CTC subjects (p < 0.001). No interference of bowel preparation with daily activities was reported in 80% of subjects in the r-CTC group as compared to 53% of subjects in the f-CTC group (p < 0.001). In post-examination questionnaire, average scores for discomfort of the procedure were not significantly different between r-CTC (3.53 ± 0.04) and f-CTC (3.59 ± 0.04) groups (p = 0.84). Reduced bowel preparation is better tolerated than full preparation for screening CT colonography. • Reduced bowel preparation is better tolerated than full preparation for screening CT colonography. • Procedure-related discomfort of screening CT colonography is not influenced by bowel preparation. • Males tolerate bowel preparation and CT colonography screening procedure better than females.

Identifiants

pubmed: 30402705
doi: 10.1007/s00330-018-5808-1
pii: 10.1007/s00330-018-5808-1
doi:

Substances chimiques

Cathartics 0

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

2457-2464

Subventions

Organisme : Regione Toscana (IT)
ID : POR CREO FESR 1.1c
Organisme : Ente Cassa di Risparmio di Firenze (IT)
ID : 2012.0742A2202.3931

Références

Gut. 2012 Nov;61(11):1552-9
pubmed: 22198714
Br J Health Psychol. 2012 May;17(2):432-45
pubmed: 22106985
J Natl Cancer Inst. 2015 Dec 30;108(2):
pubmed: 26719225
CA Cancer J Clin. 2018 Jul;68(4):250-281
pubmed: 29846947
Endoscopy. 2013;45(2):142-50
pubmed: 23335011
Radiology. 2018 Mar;286(3):873-883
pubmed: 29040021
Clin Radiol. 2011 Jan;66(1):30-7
pubmed: 21147296
J Med Screen. 2005;12(1):20-7
pubmed: 15814015
Am J Gastroenterol. 2012 Dec;107(12):1777-83
pubmed: 23211845
JAMA. 2016 Jun 21;315(23):2564-2575
pubmed: 27304597
Radiology. 2017 Feb;282(2):399-407
pubmed: 27580426
Acad Radiol. 2009 Jul;16(7):780-9
pubmed: 19375954
Br J Radiol. 2012 Aug;85(1016):1085-92
pubmed: 22422379
Eur Radiol. 2010 Jan;20(1):146-56
pubmed: 19626326
Cancer. 2004 May 15;100(10):2093-103
pubmed: 15139050
Eur J Health Econ. 2018 Jun;19(5):735-746
pubmed: 28681075
Clin Pract Epidemiol Ment Health. 2018 Mar 21;14:63-69
pubmed: 29643929
J Pers Soc Psychol. 1994 Dec;67(6):1063-78
pubmed: 7815302
Br J Radiol. 2016 Dec;89(1068):20160517
pubmed: 27542076
AJR Am J Roentgenol. 2008 Jul;191(1):158-67
pubmed: 18562740
Gut. 2017 Aug;66(8):1434-1440
pubmed: 27196588
Eur J Public Health. 2016 Feb;26(1):158-68
pubmed: 26370437
Eur Radiol. 2010 Feb;20(2):348-58
pubmed: 19711082
J Med Screen. 2011;18(3):128-34
pubmed: 22045821
Eur Radiol. 2014 Jul;24(7):1477-86
pubmed: 24817084
Lancet Gastroenterol Hepatol. 2018 May;3(5):326-336
pubmed: 29472116
Trials. 2013 Mar 15;14:74
pubmed: 23497601
Ann Intern Med. 2012 May 15;156(10):692-702
pubmed: 22586008
Am J Gastroenterol. 2016 Apr;111(4):516-22
pubmed: 27021193
Eur Radiol. 2010 Feb;20(2):367-76
pubmed: 19707769
Eur Radiol. 2015 Jan;25(1):203-10
pubmed: 25149295
Lancet Oncol. 2012 Jan;13(1):55-64
pubmed: 22088831
Eur Radiol. 2016 Aug;26(8):2762-70
pubmed: 26560732
Eur Radiol. 2015 Feb;25(2):331-45
pubmed: 25278245
Am J Gastroenterol. 2004 Feb;99(2):341-9
pubmed: 15046227
Epidemiol Prev. 2012 Jan;36(1 Suppl 1):1-104
pubmed: 22418841

Auteurs

Lapo Sali (L)

Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50134, Florence, Italy. lapo.sali@unifi.it.
IFCA Hospital, Via del Pergolino 6, 50139, Florence, Italy. lapo.sali@unifi.it.

Leonardo Ventura (L)

Institute for Cancer Research, Prevention and Oncological Network (ISPRO), Via Cosimo il Vecchio 2, 50139, Florence, Italy.

Grazia Grazzini (G)

Institute for Cancer Research, Prevention and Oncological Network (ISPRO), Via Cosimo il Vecchio 2, 50139, Florence, Italy.

Alessandra Borgheresi (A)

School of Radiology, Università Politecnica delle Marche, Piazza Roma 22, 60121, Ancona, Italy.

Silvia Delsanto (S)

im3D S.p.A, Via Livorno 60, 10153, Turin, Italy.

Massimo Falchini (M)

Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50134, Florence, Italy.

Beatrice Mallardi (B)

Institute for Cancer Research, Prevention and Oncological Network (ISPRO), Via Cosimo il Vecchio 2, 50139, Florence, Italy.

Paola Mantellini (P)

Institute for Cancer Research, Prevention and Oncological Network (ISPRO), Via Cosimo il Vecchio 2, 50139, Florence, Italy.

Stefano Milani (S)

Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50134, Florence, Italy.

Stefano Pallanti (S)

Department of Health Sciences, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.

Marco Zappa (M)

Institute for Cancer Research, Prevention and Oncological Network (ISPRO), Via Cosimo il Vecchio 2, 50139, Florence, Italy.

Mario Mascalchi (M)

Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50134, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH